Oncologie

, 13:537 | Cite as

Diagnostic moléculaire des hémopathies lymphoïdes matures

Synthèse / Review Article
  • 40 Downloads

Résumé

La compréhension des mécanismes moléculaires associés aux hémopathies lymphoïdes a considérablement évolué ces dernières années du fait des avancées technologiques. Des marqueurs moléculaires ont été identifiés, permettant de mieux poser le diagnostic initial. Des réarrangements géniques peuvent aider à affirmer une clonalité ou préciser l’entité clinique. Certainsmarqueurs sontégalementrecherchéspour leur valeur pronostique. Enfin, des réarrangements peuvent être utilisés pour évaluer la maladie résiduelle au cours de l’évolution.

Mots clés

Lymphomes Lymphoprolifération Diagnostic moléculaire Lymphocytes B 

Molecular diagnosis of mature lymphoproliferative disorders

Abstract

The understanding of the molecular mechanisms associated to lymphoid neoplasia has significantly improved in recent years due to technological advances. Molecular markers have been identified, allowing initial diagnosis. Genomic rearrangements can help to affirm clonality or indicate the disease entity. Some markers are also researched for their prognostic value. Finally, some rearrangements can be used for residual disease assessment during clinical course.

Keywords

Lymphomas Lymphoproliferation Molecular diagnosis B lymphocytes 

Références

  1. 1.
    Alizadeh AA, Eisen MB, Davis RE, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503–511PubMedCrossRefGoogle Scholar
  2. 2.
    Brüggemann M, White H, Gaulard P, et al (2007) Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 21: 215–221PubMedCrossRefGoogle Scholar
  3. 3.
    Campo E, Swerdlow SH, Harris NL, et al. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and pratical applications. Blood 117: 5019–5032PubMedCrossRefGoogle Scholar
  4. 4.
    Fu K, Weisenburger DD, Greiner TC, et al (2005) Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 106: 4315–4321PubMedCrossRefGoogle Scholar
  5. 5.
    Ghia P, Stamatopolos K, Belessi C, et al. (2007) ERIC recommandations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 21: 1–3PubMedCrossRefGoogle Scholar
  6. 6.
    Hamblin TJ, Davis Z, Gardiner A, et al (1999) Unmutated IG V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848–1854PubMedGoogle Scholar
  7. 7.
    Hans CP, Weisenburger DD, Greiner TC, et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275–282PubMedCrossRefGoogle Scholar
  8. 8.
    Lossos IS, Czerwinski DK, Alizadeh AA, et al (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350: 1828–1837PubMedCrossRefGoogle Scholar
  9. 9.
    Mozos A, Royo C, De Jong D, et al. (2009) SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Hematologica 94: 1555–1562CrossRefGoogle Scholar
  10. 10.
    Pott C, Hoster E, Delfau-Larue MH, et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115: 3215–3223PubMedCrossRefGoogle Scholar
  11. 11.
    Rambaldi A, Carlotti E, Oldani E, et al. (2005) Quantitative PCR of bone marrow BCL2/IgH-cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 105: 3428–3433PubMedCrossRefGoogle Scholar
  12. 12.
    Schraders M, de Jong D, Kluin P, et al (2005) Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 205: 329–335PubMedCrossRefGoogle Scholar
  13. 13.
    Van Dongen JJM, Langerak AW, Brüggemann M, et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257–2317PubMedCrossRefGoogle Scholar
  14. 14.
    Wlodarskal I, Dierickx D, Vanhentenrijk V, et al (2008) Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 111: 5683–5690CrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2011

Authors and Affiliations

  1. 1.Service d’hématologie biologique, laboratoire de biologie moléculaireCHU PontchaillouRennes Cedex 9France

Personalised recommendations